4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

SCHEDULE 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

10-Q - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

S-3 - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

10-Q - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

SCHEDULE 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

424B5 - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

BTIG Research downgraded Orchestra BioMed from Buy to Neutral

BTIG Research initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $12.00

Barclays initiated coverage of Orchestra BioMed with a rating of Overweight and set a new price target of $16.00

H.C. Wainwright initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $14.00

B. Riley Securities initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $15.00

Jefferies initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $14.00

Piper Sandler initiated coverage of Orchestra BioMed with a rating of Overweight and set a new price target of $15.00

Chardan Capital Markets initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $20.00

NEW HOPE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company's participation appear below: 2025 Jefferies London Healthcare Conference – November 17-20, 2025 (London, UK) Management will host one-on-one meetings with investors on Tuesday, November 18. Piper 37th Annual Healthcare Conference – December 2-4, 2025 (New York, NY) M

Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and Ligand, as well as $30 million from TerumoInitiated patient enrollments in the Virtue Trial evaluating Virtue® Sirolimus AngioInfusion™ Balloon ("Virtue SAB") trial versus commercially available paclitaxel-coated balloon Demonstrated partnership-driven business model execution with expanded strategic collaboration with Medtronic and new right of first refusal agreement with Terumo NEW HOPE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO,

NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will host a business update call on Wednesday, November 12th at 8:00 AM ET. The business update will focus on recent significant clinical, strategic and financing developments, including the Company's additional strategic investment from and collaboration expansion with Medtronic, its new strategic capital relationship with Ligand, its new right of first refusal agr

New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreementTerumo to pay a total of $30 million to Orchestra BioMedOrchestra BioMed retains all development and distribution rights to Virtue SAB in all indicationsOrchestra BioMed recently initiated patient enrollment for the Virtue Trial, its U.S. pivotal IDE trial of Virtue SAB in the treatment of coronary in-stent restenosis ("ISR") NEW HOPE, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with mar

Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus ("SirolimusEFRTM")The Virtue Trial is the first U.S. investigational device exemption ("IDE") head-to-head randomized coronary pivotal trial evaluating a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) Coronary in-stent restenosis ("ISR"), the clinical focus of the Virtue Trial, is a difficult-to-treat and serious complication of coronary stenting that increases the risk of life-threatening heart problems, affecting an estimated 100,000 pati

Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart diseaseOrchestra BioMed and Medtronic (NYSE:MDT) have a strategic collaboration to develop and commercialize AVIM Therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, an estimated global population of over 750,000 patients annuallyAVIM Therapy has received FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, an estimated U.S. population of over 7.7 million patients NEW HOPE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Orches

Results from long-term follow up of patients treated with atrioventricular interval modulation ("AVIM") therapy show blood pressure-lowering effects are sustained for years after activation, reversible with no observed rebound hypertension upon deactivation of treatment, and reproducible upon reactivation following a washout periodSimultaneous peer-reviewed publication of AVIM therapy mechanistic and clinical results Orchestra BioMed and Medtronic (NYSE:MDT) have a strategic collaboration to develop and commercialize AVIM therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, an estimated global population of over 750,000 patients annuallyAVIM therapy h

Data from acute and chronic pressure-volume loop studies support the mechanism of action and show a favorable impact of AVIM therapy on blood pressure and cardiovascular hemodynamicsAVIM therapy drove statistically significant reductions in systolic blood pressure, intra-cardiac volumes, total peripheral resistance and stroke work, with no adverse impact on stroke volume or contractility.Orchestra BioMed and Medtronic (NYSE:MDT) have a strategic collaboration for the development of AVIM therapy for treatment of uncontrolled hypertension in patients indicated for a pacemaker; over 750,000 patients annually that receive pacemakers worldwide are also believed to have hypertension. AVIM therapy

Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation ("AVIM") therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failure with preserved ejection fraction ("HFpEF")Hypertension is the leading cause of diastolic dysfunction and the most common comorbidity in older patients indicated for a pacemaker NEW HOPE, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the publication

Secured over $111 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by over $71 million in committed capital from Medtronic and LigandAchieved multiple FDA regulatory milestones: Breakthrough Device Designation for AVIM therapy; approval for expanded BACKBEAT study enrollment criteria, and IDE approval for a U.S. pivotal Virtue SAB trial versus commercially available paclitaxel-coated balloon NEW HOPE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients t

SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation ("AVIM") therapy for patients who have uncontrolled hypertension and a pacemaker indicationA globally recognized thought leader and innovator in cardiovascular technologies, including electrophysiology and cardiac rhythm management, Dr. Reddy currently serves as the Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital, the Director of Electrophysiology for the Mount Sinai Health System, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine a

Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe

John Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of Directors Most recently, Mr. Mack served as Medtronic's President of Cardiac Surgery; Previous Medtronic roles include Vice President, Business Development, Strategy & Portfolio Management NEW HOPE, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of John Mack to its Board of Directors, effective as of July 29, 2024. Mr. Mack brings over 30 years

David Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers; formerly Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott VascularMr. Pacitti brings nearly 30 years of experience in cardiovascular device and procedural imaging experience to the Orchestra BioMed Board of Directors after previously serving as a strategic advisor during the formation of the company NEW HOPE, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward shar

FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company's Board of Directors (the "Board"). Mr. Durbin has more than 25 years of executive leadership, finance and clinical development experience, including the execution of over $5 billion in financings and merger transactions. In addition, the Company announced that David Hochman and Darren Sherman, independent members of the Board, have stepped down from the Board due to time requirements of their roles as Chief Executive Offi

U.S. Food and Drug Administration ("FDA") granted Investigational Device Exemption ("IDE") approval with conditions for Virtue SAB® coronary in-stent restenosis ("ISR") U.S. pivotal study (in collaboration with Terumo Corporation ("Terumo")); study expected to start before the end of 2023BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023 NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships

Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly created Executive Vice President (EVP) of Corporate Development and Strategy role Andrew Taylor joins as Chief Financial Officer (CFO) with over 20 years of CFO experience with emerging growth companies, the last 15 of which were spent in the medical device sector NEW HOPE, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-rewa

Completed business combination and listing on Nasdaq generating gross proceeds of approximately $70 millionBackBeat CNT™ global pivotal study in hypertensive pacemaker patients on track for initiation in the second half of 2023 in collaboration with MedtronicVirtue SAB® U.S. pivotal study in coronary in-stent restenosis ("ISR") start planned for the second half of 2023 in collaboration with Terumo NEW HOPE, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2023 financial r

NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will host a business update call on Wednesday, November 12th at 8:00 AM ET. The business update will focus on recent significant clinical, strategic and financing developments, including the Company's additional strategic investment from and collaboration expansion with Medtronic, its new strategic capital relationship with Ligand, its new right of first refusal agr

Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for global development and commercialization of BackBeat Cardiac Neuromodulation Therapy™ (CNT), now also known as Atrioventricular Interval Modulation ("AVIM") therapy, for hypertensive pacemaker patientsBACKBEAT global pivotal study is expected to start before the end of 2023 IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients Orc